We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-17.58%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$495M
AUM Growth
-$71.6M
Cap. Flow
+$24.8M
Cap. Flow %
5.02%
Top 10 Hldgs %
75.58%
Holding
34
New
4
Increased
11
Reduced
4
Closed
7

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$30.1M
2
CASC
Cascadian Therapeutics, Inc.
CASC
+$22.6M
3
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$17.3M
4
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$8.2M
5
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$4.3M

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$10.4M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$9.68M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$5.98M
4
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$4.53M
5
ATXS
Astria Therapeutics
ATXS
+$2.75M

Sector Composition

Rank Sector Weight
1 Healthcare 62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$614M
$50.8M 10.26%
5,820,001
+3,227,698
+125% +$30.1M
CCXI
2
DELISTED
ChemoCentryx, Inc.
CCXI
$45.8M 9.26%
7,573,493
+303,480
+4% +$2.19M
CASC
3
DELISTED
Cascadian Therapeutics, Inc.
CASC
$44.8M 9.06%
2,726,756
+1,101,060
+68% +$22.6M
ARRY
4
DELISTED
Array Biopharma Inc
ARRY
$44.1M 8.92%
9,680,630
+511,354
+6% +$3.03M
CNCE
5
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$42.3M 8.55%
2,255,168
-266,284
-11% -$4.53M
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$36.3M 7.34%
1,702,654
+120,246
+8% +$3.33M
LOXO
7
DELISTED
Loxo Oncology, Inc
LOXO
$26.8M 5.41%
1,531,108
-83,973
-5% -$1.64M
VTAE
8
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$26.2M 5.28%
2,375,933
+771,318
+48% +$8.2M
FWP
9
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$23.9M 4.84%
145,189
+1,049
+0.7% +$220K
OMED
10
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$22.8M 4.61%
1,376,113
+111,398
+9% +$2.23M
CTIC
11
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$14.6M 2.95%
+1,000,000
New +$17.3M
CYTK icon
12
Cytokinetics
CYTK
$10.9B
$14.1M 2.85%
2,106,989
– –
ARQL
13
DELISTED
Arqule Inc
ARQL
$12.3M 2.48%
6,566,148
+135,440
+2% +$234K
TBRA
14
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$11.4M 2.29%
1,175,233
– –
QLTI
15
DELISTED
QLT Inc
QLTI
$9.94M 2.01%
3,737,446
– –
XENE icon
16
Xenon Pharmaceuticals
XENE
$6.2B
$8.55M 1.73%
1,035,572
+356,808
+53% +$3.54M
ONCT
17
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$8.19M 1.65%
7,695
– –
GYRE icon
18
Gyre Therapeutics
GYRE
$648M
$4.76M 0.96%
9,074
+623
+7% +$950K
SVRA icon
19
Savara
SVRA
$1.14B
$2.96M 0.6%
72,915
-103
-0.1% -$3.29K
CALA
20
DELISTED
Calithera Biosciences, Inc
CALA
$2.48M 0.5%
+22,825
New +$2.96M
VIRX
21
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.02M 0.41%
+11,905
New +$4.3M
GBIM
22
DELISTED
GLOBEIMMUNE INC COM STK (DE)
GBIM
$1.77M 0.36%
678,400
– –
FLNA
23
Filana Therapeutics
FLNA
$46.4M
$1.7M 0.34%
+132,680
New +$1.67M
VXRT
24
DELISTED
Vaxart
VXRT
$695K 0.14%
31,889
– –
APTO
25
DELISTED
Aptose Biosciences, Inc.
APTO
$179K 0.04%
92
-142
-61% -$316K
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2015 Portfolio in Review

As of Q3 2015, BVF Inc held 34 positions worth $495M, down 13% from $567M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

BVF Inc deployed $24.8M of net new capital in Q3 2015, opening 4 new positions and adding to 11 existing holdings. Its largest new stake was CTI BioPharma Corp. (DE) Common Stock: 1,000,000 shares worth $14.6M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 62% a quarter earlier.

On the sell side, the largest reduction was Concert Pharmaceuticals, Inc., an estimated $4.53M trimmed.

  • BVF Inc's largest Q3 2015 buy was CTI BioPharma Corp. (DE) Common Stock: 1,000,000 shares worth $14.6M.
  • BVF Inc added most to Ironwood Pharmaceuticals in Q3 2015, an estimated $30.1M increase.
  • BVF Inc's biggest Q3 2015 reduction was Concert Pharmaceuticals, Inc., cutting an estimated $4.53M.
  • BVF Inc fully exited Exelixis in Q3 2015, selling an estimated $10.4M.
  • BVF Inc's ten largest holdings make up 76% of its $495M portfolio in Q3 2015.
  • BVF Inc opened 4 new positions and closed 7 in Q3 2015.
  • BVF Inc's portfolio value fell 13% quarter-over-quarter to $495M.

Based on BVF Inc's 13F filing for Q3 2015, filed 16 Nov 2015.